ACTIVE

EURO - MEDIC

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result2,2 M €+1,1 %over 1 year

Revenue25,1 M €+2,9 %over 1 year

Equity3,2 M €+3,4 %over 1 year

Workforce4,1 ETP-2,4 %over 1 year

Identity

Source · BCE/KBO

EURO - MEDIC is a Public limited company incorporated in 2000. Its registered office is in Deinze. It employs on average 4,1 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0473.175.601
Incorporation: 31/10/2000
Legal form: Public limited company
Registered office: Poeldendries 49
9850 Deinze · FlandreSee on map
Contributed capital: 113 769,82 €
Latest accounts: 31/12/2025
Average workforce: 4,1 ETP

Joint committees (2)

Signals

ProfitableLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 21 filings

Trend over 21 financial years

	2025		2024		2023		2022		2021
Income statement
Revenue	25,1 M €	+2.9%	24,4 M €	+1.8%	24 M €	+4.7%	22,9 M €	+11.0%	20,7 M €
EBITDA	2,6 M €	-14.2%	3 M €	-1.2%	3 M €	+9.1%	2,8 M €	+57.7%	1,8 M €
Operating result	2,4 M €	-18.3%	3 M €	-1.1%	3 M €	+9.5%	2,8 M €	+57.0%	1,8 M €
Net result	2,2 M €	+1.1%	2,2 M €	-10.8%	2,5 M €	+19.8%	2,1 M €	+54.7%	1,3 M €
Balance sheet
Equity	3,2 M €	+3.4%	3,1 M €	-20.8%	3,9 M €	-12.3%	4,4 M €	-17.6%	5,4 M €
Total assets	14,1 M €	+83.4%	7,7 M €	+17.2%	6,5 M €	+3.0%	6,4 M €	-26.5%	8,6 M €
Cash	1,1 M €	-36.7%	1,8 M €	+23.0%	1,5 M €	-15.3%	1,7 M €	-46.8%	3,2 M €
Debts	10,8 M €	+134%	4,6 M €	+72.7%	2,7 M €	+38.1%	1,9 M €	-41.1%	3,3 M €
Other
Workforce	4,1 ETP	-2.4%	4,2 ETP	-16.0%	5,0 ETP	+11.1%	4,5 ETP	-10.0%	5,0 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 10 M€ and 25 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 16 ended

Active mandates

Danny Vander Cruyssen

Director · since 09 novembre 2023

Active

Ended mandates

DANNY VANDER CRUYSSEN

Director · since 15 juin 2020 · until 13 juin 2026

Ended

Danny Vander Cruyssen

Director · since 14 juin 2020 · until 13 juin 2026

Ended

PharmaCross

Director · since 14 juin 2020 · until 13 juin 2026 · 0888.580.475

Represented by Danny VANDER CRUYSSEN

Ended

SOFIE VANDER CRUYSSEN

Director · since 14 juin 2020 · until 13 juin 2026

Ended

Other companies at this address

Poeldendries 49 9850 Deinze

Company	CBE no.
PharmaCross● Active	0888.580.475

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	11/08/2026	26/06/2025	16/07/2024	14/07/2023	13/07/2022	30/08/2021
General meeting	10/05/2026	10/05/2025	10/05/2024	10/05/2023	10/05/2022	10/05/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 21 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	10/05/2026	11/08/2026	Dutch	PDF
Full model	31/12/2024	10/05/2025	26/06/2025	Dutch	PDF
Full model	31/12/2023	10/05/2024	16/07/2024	Dutch	PDF
Full model	31/12/2022	10/05/2023	14/07/2023	Dutch	PDF
Full model	31/12/2021	10/05/2022	13/07/2022	Dutch	PDF
Full model	31/12/2020	10/05/2021	30/08/2021	Dutch	PDF
Full model	31/12/2019	11/05/2020	01/10/2020	Dutch	PDF
Abridged model	31/12/2018	10/05/2019	26/08/2019	Dutch	PDF
Abridged model	31/12/2017	11/05/2018	29/08/2018	Dutch	PDF
Abridged model	31/12/2016	10/05/2017	17/07/2017	Dutch	PDF
Abridged model	31/12/2015	10/05/2016	11/07/2016	Dutch	PDF
Abridged model	31/12/2014	11/05/2015	26/08/2015	Dutch	PDF
Abridged model	31/12/2013	10/05/2014	29/08/2014	Dutch	PDF
Abridged model	31/12/2012	29/03/2013	30/08/2013	Dutch	PDF
Abridged model	31/12/2011	10/05/2012	26/07/2012	Dutch	PDF
Abridged model	31/12/2010	10/05/2011	16/05/2011	Dutch	PDF
Abridged model	31/12/2009	10/05/2010	21/05/2010	Dutch	PDF
Abridged model	31/12/2008	11/05/2009	30/07/2009	Dutch	PDF
Abridged model	31/12/2007	10/05/2008	06/06/2008	Dutch	PDF
Abridged model	31/12/2006	14/09/2007	27/09/2007	Dutch	PDF
Abridged model	31/12/2004	30/06/2005	27/06/2007	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 10 M€ and 25 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 16 ended

Active mandates

Danny Vander Cruyssen

Director · since 09 novembre 2023

Active

Ended mandates

DANNY VANDER CRUYSSEN

Director · since 15 juin 2020 · until 13 juin 2026

Ended

Danny Vander Cruyssen

Director · since 14 juin 2020 · until 13 juin 2026

Ended

PharmaCross

Director · since 14 juin 2020 · until 13 juin 2026 · 0888.580.475

Represented by Danny VANDER CRUYSSEN

Ended

SOFIE VANDER CRUYSSEN

Director · since 14 juin 2020 · until 13 juin 2026

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Restructuring08/08/2025
KAPITAAL - AANDELEN - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
PDF
Restructuring27/05/2025
RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
PDF
Mandates14/11/2023
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - ONTSLAGEN - BENOEMINGEN
PDF
Mandates19/10/2021
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares21/06/2018
KAPITAAL - AANDELEN
PDF
Mandates27/08/2015
ONTSLAGEN - BENOEMINGEN
PDF
Mandates09/07/2015
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares18/04/2014
KAPITAAL - AANDELEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

2025
Annual accounts 20252,2 M €↑
2024
Annual accounts 20242,2 M €↓
2023
Annual accounts 20232,5 M €↑
2022
Annual accounts 20222,1 M €↑
2021
Annual accounts 20211,3 M €↑
2020
Annual accounts 20201,1 M €↑
2019
Annual accounts 20191 M €↑
2018
Annual accounts 2018511,4 k €↓
2017
Annual accounts 2017534,9 k €↑
2016
Annual accounts 2016464,3 k €↑
2015
Annual accounts 2015227,1 k €↑
2014
Annual accounts 2014133,4 k €↑
2013
Annual accounts 2013101,6 k €↑
2012
Annual accounts 201290,7 k €↑
2011
Annual accounts 201146,6 k €↓
2010
Annual accounts 2010124,1 k €↑
2009
Annual accounts 200942,4 k €↑
2008
Annual accounts 200820,4 k €↓
2007
Annual accounts 200795,1 k €↑
2006
Annual accounts 2006-8,1 k €↑
2004
Annual accounts 2004-22,4 k €
31/10/2000
IncorporationPublic limited company

EURO - MEDIC

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline